BioNTech SE

BioNTech SE engages in the development of novel medicines at the intersection of immunology and synthetic biology. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Ozlem Tureci and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioNTech reports robust 2022 earnings, eyes growth in oncology and infectious diseases

BioNTech's strong financial performance in 2022 sets the stage for continued growth in 2023, with a focus on expanding its vaccine portfolio, advancing oncology programs, and navigating the evolving landscape of COVID-19. The company's strategic priorities align with market demands for infectious disease and oncology solutions, positioning BioNTech for future success and profitability.

BioNTech posts robust Q1 results, eyes growth in vaccines and oncology

BioNTech's Q1 2023 performance reflects strong financial results and promising developments in its vaccine and oncology programs.
While facing challenges such as seasonal trends and data constraints, the company is strategically positioned to leverage opportunities in commercial planning and therapeutic advancements.
With a focus on synergistic partnerships and innovative technologies, BioNTech aims to maintain its competitive edge in the biopharmaceutical industry.
The company's commitment to enhancing existing platforms and exploring new growth avenues underscores its resilience and adaptability in a dynamic market environment.

BioNTech reports mixed Q2 results, focuses on innovation and growth

BioNTech's Q2 2023 performance reflects a mix of strong revenue generation and financial challenges, emphasizing the importance of strategic focus.
The company's strengths lie in its innovative collaborations, pipeline advancements, and preparedness for market demands, despite facing financial losses.
Navigating challenges in financial sustainability, market competition, and stakeholder communication will be crucial for BioNTech's future growth and success.

BioNTech adjusts revenue guidance amidst vaccine demand challenges

BioNTech's Q3 2023 performance reflected revenue challenges from lower COVID-19 vaccine demand and write-downs, prompting revised revenue guidance.
Despite challenges, the company showcased strengths in vaccine development, oncology advancements, and strategic cost management initiatives.
Opportunities lie in shared R&D expenses, long-term growth prospects from combination vaccines, and maintaining financial strength during market transition.

BioNTech reports strong Q4 earnings, eyes diversified product expansion

BioNTech is strategically investing in expanding its product portfolio while navigating uncertainties in COVID-19 vaccine revenues. The company aims to transform into a multiproduct company by 2030, focusing on oncology and infectious diseases.

BioNTech advances oncology pipeline, eyes growth amid financial challenges

BioNTech is making significant strides in its oncology pipeline, aiming for multiple product launches by 2026 and focusing on cancer vaccines and mRNA treatments.
While facing financial losses and short-term profitability challenges, the company remains optimistic about its growth trajectory and revenue potential.
Strategic investments in technology platforms, commercial readiness, and partnerships position BioNTech for sustainable growth and value enhancement.
Balancing cost control, revenue generation, and clinical execution will be crucial for BioNTech to capitalize on opportunities and navigate challenges effectively.

BioNTech reports Q2 progress in oncology pipeline amid financial challenges

BioNTech's Q2 2024 earnings call highlighted progress in oncology and COVID-19 vaccines, with total revenues of EUR 129 million but a net loss of EUR 808 million. The company remains focused on advancing innovative therapies and expanding its global manufacturing capabilities.

BioNTech reports robust Q3 earnings, focuses on oncology pipeline

BioNTech's Q3 2024 performance was strong, driven by COVID-19 vaccines and oncology trials.
While facing revenue challenges in certain regions, the company remains focused on growth.
Opportunities lie in advancing oncology pipeline and demonstrating product potential.
Maintaining a strong cash position provides flexibility for future investments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of BioNTech SE (“BioNTech” or the “Company”) (NASDAQ: BNTX) investors concerning the Company's possible violations of the federal securities laws. If you suffered a loss on your BioNTech investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, y.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of BioNTech SE (BNTX) on Behalf of Investors

LOS ANGELES, CA / ACCESSWIRE / January 24, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioNTech SE ("BioNTech" or "the Company") (NASDAQ:BNTX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 30, 2022 and October 13, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before March 12, 2024.

DEADLINE ACTION REMINDER: The Schall Law Firm Encourages Investors in BioNTech SE with Losses of $100,000 to Contact the Firm

NEW YORK , Jan. 23, 2024 /PRNewswire/ --  WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of BioNTech SE (NASDAQ: BNTX) between March 30, 2022 and October 13, 2023, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed.

ROSEN, A LEADING LAW FIRM, Encourages BioNTech SE Investors to Secure Counsel Before Important Deadline in Securities Class Action - BNTX

NEW YORK , Jan. 23, 2024 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in BioNTech SE ("BioNTech" or the "Company") (NASDAQ: BNTX) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of BioNTech investors who were adversely affected by alleged securities fraud between March 30, 2022 and October 13, 2023.

SHAREHOLDER ALERT: Levi & Korsinsky Notifies BioNTech SE (BNTX) Investors of a Class Action Lawsuit and Upcoming Deadline

LOS ANGELES, CA / ACCESSWIRE / January 22, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioNTech SE ("BioNTech" or "the Company") (NASDAQ: BNTX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 30, 2022 and October 13, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before March 12, 2024.

DEADLINE ACTION NOTICE: The Schall Law Firm Encourages Investors in BioNTech SE with Losses In Excess of $100,000 to Contact the Firm

BioNTech and its partner Duality Biologics said on Monday they initiated a late-stage trial testing their precision drug against a certain type of breast cancer, taking on a rival partnership between AstraZeneca and Daiichi Sankyo.

BioNTech challenges AstraZeneca with breast cancer precision drug trial

MAINZ, Germany and SHANGHAI, China, January 22, 2024 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Duality Biologics (Suzhou) Co., Ltd. (“DualityBio”) today announced that the first patient with metastatic breast cancer has been treated in a pivotal Phase 3 trial evaluating the efficacy and safety of the next-generation antibody-drug conjugate (“ADC”) candidate BNT323/DB-1303 targeting the Human Epidermal Growth Factor Receptor 2 (“HER2”), a cancer cell surface protein.

BioNTech and DualityBio Initiate Pivotal Phase 3 Trial Of Antibody-Drug Conjugate Candidate BNT323/DB-1303 in Metastatic Breast Cancer

NEW YORK--(BUSINESS WIRE)---- $BNTX #classaction--Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against BioNTech SE (“BioNTech” or “the Company”) (NASDAQ: BNTX) and certain of its officers. Class Definition: This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired BioNTech securit.

BNTX INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that BioNTech SE Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

RADNOR, Pa. , Jan. 21, 2024 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against BioNTech SE ("BioNTech") (NASDAQ: BNTX).

Kessler Topaz Meltzer & Check, LLP Announces Investor Securities Fraud Class Action Lawsuit Filed Against BioNTech SE

RADNOR, Pa.--(BUSINESS WIRE)-- #classaction--The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against BioNTech SE (“BioNTech”) (NASDAQ: BNTX). The action charges BioNTech with violations of the federal securities laws, including omissions and fraudulent misrepresentations relating to the company's business, operations, and prospects. As a result of BioNTech' s materially misleading statements and omissions to the publ.

BNTX ANNOUNCEMENT: Kessler Topaz Meltzer & Check, LLP Announces Investor Securities Fraud Class Action Lawsuit Filed Against BioNTech SE (BNTX)

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of BioNTech SE (“BioNTech” or the “Company”) (NASDAQ: BNTX) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On August 8, 2022, BioNTech released its second quarter 2022 financial results, missing consensus estimates, which the Company attributed to the “dynamic” development of the pandem.

The Law Offices of Frank R. Cruz Announces Investigation of BioNTech SE (BNTX) on Behalf of Investors

NEW YORK, NY / ACCESSWIRE / January 19, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioNTech SE ("BioNTech" or "the Company") (NASDAQ:BNTX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 30, 2022 and October 13, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before March 12, 2024.

IMPORTANT DEADLINE NOTICE: The Schall Law Firm Encourages Investors in BioNTech SE with Losses In Excess of $100,000 to Contact the Firm

SAN DIEGO--(BUSINESS WIRE)---- $BNTX #BioNTechSE--BioNTech SE (BNTX) Allegedly Misled Investors Regarding its Business Prospects.

BioNTech SE (BNTX) Shareholder Alert: Robbins LLP Reminds Investors of Class Action Filed Against BioNTech SE

If you suffered losses exceeding $100,000 investing in BioNTech stock or options between March 30, 2022 and October 13, 2023 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330  (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/BNTX.

BIONTECH INVESTOR DEADLINE APPROACHING: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In BioNTech To Contact Him Directly To Discuss Their Options

LOS ANGELES, CA / ACCESSWIRE / January 17, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against BioNTech SE ("BioNTech" or "the Company") (NASDAQ:BNTX) for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 30, 2022 and October 13, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before March 12, 2024.

IMPORTANT INVESTOR NOTICE: The Schall Law Firm Encourages Investors in BioNTech SE with Losses In Excess of $100,000 to Contact the Firm

NEW YORK , Jan. 16, 2024 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of BioNTech SE (NASDAQ: BNTX) between March 30, 2022 and October 13, 2023, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed.

ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages BioNTech SE Investors to Secure Counsel Before Important Deadline in Securities Class Action - BNTX

Advanced Micro Devices

Amazon

Alibaba

CrowdStrike

Chevron

Barrick Gold

Alphabet

Madison Square Garden Sports

Trade Desk

2023 was an incredibly strong year for U.S. stocks but many believe the S&P 500 will push further up in the new year. To play that continued strength, our experts have picked top 10 stocks to buy in 2024.

Top 10 stocks to buy in 2024

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of BioNTech SE (NASDAQ: BNTX) between March 30, 2022 and October 13, 2023, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 12, 2024. SO WHAT: If you purchased BioNTech securities during the Class Period yo.

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages BioNTech SE Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – BNTX

SHANGHAI , Jan. 10, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269. HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), today announced that its Research Service Unit (R in CRDMO) has signed a research service agreement with BioNTech SE (Nasdaq: BNTX, "BioNTech"), a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases.

WuXi Biologics Announces Research Service Agreement with BioNTech on Discovering Investigational Monoclonal Antibodies for Developing Next-Generation Therapeutic Product Candidates

BioNTech SE (BNTX) 42nd Annual J.P. Morgan Healthcare Conference (Transcript)

COVID-19 vaccine maker BioNTech on Tuesday forecast total company revenues of about 3 billion euros ($3.28 billion)for 2024, as it works to scale up its oncology business with product launches in the coming years.

BioNTech expects 2024 revenues of about $3.3 bln

Mainz, Germany, January 9, 2024 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) provided its full year 2024 revenue guidance as part of its outlined 2024 strategic priorities today at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, California.

BioNTech Outlines 2024 Strategic Priorities at the 42nd Annual J.P. Morgan Healthcare Conference

BioNTech is diversifying its portfolio beyond its COVID-19 vaccine, focusing on antibody-drug conjugates (ADCs) and novel vaccines. The company has acquired MediLink Therapeutics' ADC technology and is targeting HER3 protein-related tumors in cancer treatment. Despite a decline in revenue and profit, BioNTech remains financially robust with strong cash reserves and a solid current ratio.

BioNTech's Strategic Shift: Diversifying Into Cancer Therapeutics

BioNTech and Pfizer's COVID-19 vaccine, COMIRNATY, generated $36.8 billion in sales in 2021, making it the highest-selling pharmaceutical product in a single year. BioNTech's stock has faced challenges due to competition and declining COVID-19 demand, leading to the stock dropping 29% this year. However, it has a promising pipeline of therapies in ongoing trials and the potential for recurring revenue from annual COVID-19 booster shots.

BioNTech's COVID-19 Success Paves The Way For A Strong Drug Pipeline

MAINZ, Germany and SHANGHAI, China, December 21, 2023 –  BioNTech SE  (Nasdaq: BNTX, “BioNTech”) and Duality Biologics (Suzhou) Co. Ltd. (“DualityBio”) today announced that the U.S. Food and Drug Administration (“FDA”) granted Breakthrough Therapy designation for BNT323/DB-1303 for the treatment of advanced endometrial cancer in patients who progressed on or after treatment with immune checkpoint inhibitors. BNT323/DB-1303 is a next-generation antibody-drug conjugate (“ADC”) candidate targeting the Human Epidermal Growth Factor Receptor 2 (“HER2”), a cell surface protein which is expressed in a range of tumor types. The designation is based on encouraging topline data from a Phase 1/2 study ( NCT05150691 ) with BNT323/DB-1303 in patients with HER2-expressing advanced endometrial cancer.

News for BioNTech SE Stock (BNTX)